An announcement was made today by Mitsubishi Tanabe Pharma America Inc. that over 4 thousand people with amyotrophic lateral sclerosis in the U.S. have been given treatment with RADICAVA and more than 1 thousand and a hundred providers of healthcare have given prescription of this therapy to one or more of their patients with amyotrophic lateral sclerosis after it became available on August 2017.
The President of Mitsubishi Tanabe Pharma America Inc., Atsushi Fujimoto stated that their focus has continued to bring a more meaningful difference in the lives of people with amyotrophic lateral sclerosis, as well as, their families. They are pursuing research into biomarkers in amyotrophic lateral sclerosis and creation of an oral formulation of RADICAVA. Be it be through their clinical research or by offering the resources to help the families in the understanding the disease and direct care, they remain as committed as ever to continue their mission.
RADICAVA is the exclusive treatment which got approval from the United States Food and Drug Administration for slowing the loss of physical function in people with amyotrophic lateral sclerosis. It is an infusion therapy which can be received by the patients in the home or in a range of clinical settings such as a physician’s officer or an ALS center. In amyotrophic lateral sclerosis, there can be no recovery of lost physical function.
Several updates were reported by MTPA regarding the effort of the firm to help people with amyotrophic lateral sclerosis and their families. Since June 2019, it is shown by our internal data that nearly 92 percent of the patients who did seek health plan coverage for treatment with RADICAVA received insurance coverage approval for their treatment. Almost 70% of patients have been on treatment for 6 or more months, according to a most recent analysis